Platelet-Activating Factor (PAF) in experimental and clinical sepsis

Shock

Volumn 7, Issue 6, 1997, Pages 391-404

  Mathiak, Guenther ^a   Szewczyk, Damian ^a   Abdullah, Fizan ^a   Ovadia, Philip ^a   Rabinovici, Reuven ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR;

ANIMAL; GRAM NEGATIVE INFECTION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SEPSIS;

ANIMALS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PLATELET ACTIVATING FACTOR; SEPSIS;

EID: 0031154407     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199706000-00001     Document Type: Review

References (147)

1. American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference: Definitions for and organ failure and guide-lines for the use of innovative therapies in sepsis. Crit Care Med 20:864-875, 1989.
2. Lowry SF: Sepsis and its complications: Clinical definitions and therapeutic prospects. Crit Care Med 22:S1-S2, 1994.
3. Bone RC: Why sepsis trials fail. JAMA 276:565-566, 1996.
4. Demling RH, Lalonde C, Ikegami K: Physiologic support of the septic patient. Surg Clin N Am 74:637-658, 1994.
5. Jacobs CO, Fronek Z, Lewis GD: Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233-1237, 1990.
6. Benveniste J, Henson PM, Cochrane CG: Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils, and platelet-activating factor. J Exp Med 136:1356-1377, 1972.
7. Benveniste J, Tence M, Varenne P, Bidault J, Polonsky J: Semi-synthesis and proposed structure of Platelet-Activating Factor (PAF): PAF-acether an alkyl ether analog of lysophosphatidylcholine [French]. C R Seances Acad Sci 289:1037-1040, 1979.
8. Blank ML, Snyder F, Byers WL, Brooks B, Muirhead EE: Antihypertensive activity of an alkyl ether analogue of phosphatidylcholine. Biochem Biophys Res Comm 90:523-534, 1979.
9. Demolpoulus CA, Pinckard RN, Hanahan DJ: Platelet-Activating Factor: Evidence of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem 254:9355-9358, 1979.
10. Henson PM: Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J Exp Med 131:287-306, 1979.
11. Camussi G, Bussolino F, Salvidio G, Baglioni C: Tumor necrosis factor/ cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med 166:1390-1404, 1987.
12. Salari H, Wong A: Generation of platelet-activating factor (PAF) by a human lung epithelial cell line. Eur J Pharmacol 175:253-259, 1990.
13. Braquet P, Touqui L, Shen T, Vargaftig BB: Perspectives in platelet-activating factor research. Pharmacol Rev 39:97-145, 1987.
14. Rabinovici R, Yue TL, Feuerstein G: Platelet-activating factor in cardiovascular stress situations. Lipids 26:1257-1263, 1991.
15. Feuerstein G, Zukowska-Grojec Z, Krausz M, Blank M, Snyder F: Cardiovascular and sympathetic effects of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine in conscious SHR and WYK rats. Clin Exp Hypertension A4:1335-1350, 1982.
16. Feuerstein G, Lux WE, Ezra D, Hayes E, Snyder F: Thyrotrophin releasing hormone blocks the hypotensive effect of platelet activating factor in unanesthetized guinea-pig. J Cardivasc Pharmacol 7:335-340, 1985.
17. Bessin P, Bonnet J, Apfel D, Soulard C, Desgroux L: Acute circulating collapse caused by platelet activating factor (PAF acether) in dogs. Eur J Pharmacol 86:403-413, 1983.
18. Argiolas L, Fabi F, del Basso P: Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: Role of platelets and cyclo-oxygenase metabolites. Br J Pharmacol 114:203-209, 1995.
19. Feuerstein G, Boyd LM, Ezra D, Goldstein RE: Effect of platelet activating factor on coronary circulation of the domestic pig. Am J Physiol 246:H446-H471, 1983.
20. Sybertz EJ, Watkins RW, Baum T, Pula K, Rivelli M: Cardiac, coronary and peripheral vascular effects of acetyl ether phosphoryl choline in the anaesthetized dog. J Pharmacol Exp Ther 232:156-162, 1984.
21. Levi R, Burke JA, Guo ZG, Hattori Y, Hoppens CM: Acetyl glyceryl ether phosphorylcholine (AGEPC): A putative mediator of cardiac anaphylaxis. Circ Res 54:117-124, 1984.
22. Camussi G, Aglietta M, Malavasi F, Tetta C, Piacibelo W: The release of platelet activating factor from human endothelial cells in culture. J Immunol 131:2397-2403, 1983.
23. Benveniste J, Boullet C, Brink C, Labat C: The actions of PAF acether (platelet activating factor) on guinea pig isolated heart preparation. Br J Pharmacol 80:81-83, 1983.
24. Bussolino F, Aglietta M, Sanavino F, Stacchini A, Lauri D, Camussi G: Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol 135:2748-2753, 1985.
25. Bussolino F, Camussi G, Aglietta M, et al: Human endothelial cells are a target for platelet activating factor. J Immunol 139:2439-2446, 1987.
26. Bourgain RH, Maes L, Braquet P, Andries R, Toqui L, Braquet M: The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on the arterial wall. Prostaglandins 30:185-197, 1985.
27. Sanchez-Crespo M, Alonso F, Inarrea P, Alvarez V, Egido J: Vascular actions of synthetic PAF-acether (a synthetic platelet activating factor in the rat), evidence for a platelet independent mechanism. Immunopharmacology 4:173-185, 1982.
28. Hwang SB, Lam MH, Lee CL, Shen TY: Releases of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema. Eur J Pharmacol 120:33-41, 1986.
29. Cox CP, Mojarad M, Attiah A: Platelet activating factor (PAF) increases pulmonary vascular permeability in awake sheep. Am Rev Resp Dis 129(suppl):A334, 1984.
30. Morley J, Page CP, Paul W: Inflammatory actions of platelet activating factor (PAF-acether) in guinea-pig skin. Br J Pharmacol 80:503-509, 1983.
31. Braquet P, Vidal RF, Braquet M, Hamard H, Vargaftig BB: Involvement of leukotrienes and PAF-acether in the increased microvascular permeability of the rabbit retina. Agent Action 15:82, 1984 (abstract).
32. Gonzalez-Crussi F, Hsueh W: Experimental models of ischemic bowel necrosis. The role of platelet activating factor and endotoxin. Am J Pathol 112:127-135, 1983.
33. Rosam AC, Wallace JL, Whittle BJ: Potent ulcerogenic actions of platelet activating factor on the stomach. Nature 319:54-56, 1986.
34. Smallbone BW, Taylor NE, McDonald JW: Effect of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep. J Pharmacol Exp Ther 242:1035-1040, 1987.
35. Lang HL, Dobrescu C, Hargrove DM, Bagby GJ, Spitzer JJ: Platelet-activating factor-induced increases in glucose kinetics. Am J Physiol 254:E193-E200, 1988.
36. Boruff JS, Karlstad MD: Effect of platelet-activating factor on basal and insulin-mediated system A amino acid transport in rat soleus muscle. Circ Shock 40:75-80, 1993.
37. Buripakdi D, Karlstad MD: The role of platelet-activating factor in alterations of system A amino transport in rat soleus and extensor digitorum longus muscle during endotoxic shock. Shock 2:53-59, 1994.
38. Hayashi H, Kudo I, Nojima S, Inoue K: Biological response of guinea pig peritoneal macrophages to platelet-activating factor. Lipids 26:1193-1199, 1991.
39. Bonavida B, Mencia-Huerta JM, Braquet P: Effects of platelet activating factor on peripheral blood monocytes: Induction and priming for TNF secretion. J Lipid Mediat 2 (suppl):S65-S76, 1990.
40. Bonavida B, Mencia Huerta JM, Braquet P: Effect of platelet activating factor on monocyte activation and production of tumor necrosis factor. Int Arch Allergy Appl Immunol 88:157-160, 1989.
41. Rola-Pleszczyski M, Bosse J, Bissonnette E, Dubois C: PAF-acether enhances the production of tumor necrosis factor by human and rodent lymphocytes and macrophages. Prostaglandins 5:802, 1988 (abstract).
42. Braquet P, Hosford D, Koltz P, Guilbaud J, Paubert-Braquet M: Effect of platelet activating factor on tumor necrosis factor-induced superoxide generation from human neutrophils. Possible involvement of G proteins. Lipids 26:1071-1075, 1991.
43. Floch A, Bousseau A, Hetier E, Floch F, Bost P-E, Cavero I: RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat 1:349-360, 1989.
44. Heuer H: Effect of a new and specific PAF-antagonist, WEB 2086, on PAF and tumor necrosis factor induced changes in mortality and intestinal transit velocity. Prostaglandins 35:814, 1988 (abstract).
45. Sun XM, Hsueh W, Torre-Amione G: Effects of in vivo 'priming' on endotoxin induced hypotension and tissue injury. Am J Pathol 136:949-956, 1990.
46. Rabinovici R, Yue T-L, Farhat M, Smith III EF, Slivjak M, Feuerstein G: platelet activating factor (PAF) and tumor necrosis factor-α (TNF-α) interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist. J Pharmacol Exp Ther 255:256-263, 1990.
47. Rabinovici R, Esser KM, Lysko PG, et al: Priming by PAF of endotoxin induced lung injury and cardiovascular shock. Circ Res 69:12-25, 1991.
48. Rabinovici R, Bugelski P, Esser KM, Hillegass M, Vernick J, Feuerstein G: ARDS-like lung injury produced by endotoxin in platelet-activating factor-primed rats. J Appl Physiol 74:1791-1802, 1993.
49. Rabinovici R, Yeh GC, Hillegass LM, et al: Role of complement/platelet-activating factor-induced lung injury. J Immunol 5:1744-1750, 1992.
50. Rabinovici R, Bugelski PJ, et al: Tumor necrosis factor-alpha mediates endotoxin-induced lung injury in platelet-activating factor-primed rats. J Pharmacol Exp Ther 3:1550-1557, 1993.
51. Pignol B, Henane S, Sorlin B, Rola-Pleszczynski M, Mencia-Huerta JM, Braquet P: Effect of long term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells. J Immunol 145:980-984, 1990.
52. Poubelle PE, Gingras D, Demers C: Platelet-activating factor (PAF-acether) enhances the recombinant production of tumor necrosis factor-alpha and interleukin-1 by subsets of human monocytes. Immunology 72:181-187, 1991.
53. Bussolino F, Arese M, Silvestro L, Soldi R, Benfenati E, Sanavio F, Aglietta M, Bosia A, Camussi G: Involvement of a serine protease in synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-alpha or interleukin-1 alpha. Eur J Immunol 24: 3131-3139, 1994.
54. Gutierrez S, Palacios I, Egido J, Zarco P, Miguelez R, Gonzalez E, Herrero-Beaumont G: IL-1 beta and IL-6 stimulate the production of platelet-activating factor (PAF) by cultured rabbit synovial cells. Clin Exp Immunol 99:364-368, 1995.
55. Warren JS: Relationship between interleukin-1 beta and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat. Am J Pathol 141:551-560, 1992.
56. Nourshargh S, Larkin SW, Das A, Williams TJ: Interleukin-1-induced leukocyte extravasation across rat mesenteric microvessels is mediated by platelet-activating factor. Blood 85:2553-2558, 1995.
57. Rabinovici R, Sofronski M, Renz JF, et al: Platelet-activating factor mediates interleukin-2-induced lung injury in the rat. J Clin Invest 89:1669-1673, 1992.
58. Ramirez MM, Quardt SM, Kim D, Oshiro H, Minnicozzi M, Duran WN: Platelet activating factor modulates microvascular permebility through nitric oxide synthesis. Microvasc Res 50:223-234, 1995.
59. Filep JG, Foldes-Filep E: Modulation by nitric oxide of platelet-activating-factor-induced albumin extravasation in the conscious rat. Br J Pharmacol 110:1347-1352, 1993.
60. Juncos LA, Ren YL, Arima S, Ito S: Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/ nitric oxide and cyclooxygenase products. J Clin Invest 91:1374-1379, 1993.
61. MacKendrick W, Caplan M, Hsueh W: Endogenous nitric oxide protects against platelet-activating factor-induced bowel injury in the rat. Pediatr Res 34:222-228, 1993.
62. Albertini M, Clement MG: In pigs, inhaled nitric oxide (NO) counter-balances PAF-induced pulmonary hypertension. Prostaglandins Leuokot Essent Fatty Acids 51:357-362, 1994.
63. Caplan MS, Hedlund E, Hill N, MacKendrick W: The role of endogenous nitric oxide and platelet-activating factor in hypoxia-induced intestinal injury in rats. Gastroenterology 106:346-352, 1994.
64. Natsume Y, Imanishi N, Koike H, Morooka S: Effect of platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-1 hydrochloride on endotoxin-induced hypotension and hematological parameters in rats. Arzeneimittelforschung 44:1208-1213, 1994.
65. Nagaoka J, Harada K, Kimura S, et al: Inhibitory effects of the novel platelet activating factor antagonist, 1-ethyl-I[N-(2-methoxy)benoyl-N-[(2R)-2-methoxy-3-(4-octadecylcarbamoyloxy) pipendinocarbonyl-oxypropyloxy] carbonyl] aminomethyl-pyridinum chloride, in several experimentally induced shock models. Arzeneimittelforschung 41:719-24, 1991.
66. Chang SW, Feddersen CO, Henson PM, Voelkel NF: Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 79:1498-1509, 1987.
67. Doebber TW, Wu MS, Robbins JC, Ma Choy B, Chang MN, Shen TY: Platelet-activating factor (PAF) involvement in endotoxin induced hypotension in rats. Studies with PAF- receptor antagonist Kadsurenone. Biochem Biophys Res Commun 127:799-808, 1985.
68. Mozes T, Heiligers JPC, Tak CJAM, et al: Platelet activating factor is one of the mediators involved in endotoxic shock in pigs. J Lipid Med 4:309-326, 1991.
69. Klosterhalfen B, Horstmann-Jungemann K, Vogel P, et al: Time course of various inflammatory mediators during recurrent endotoxemia. Biochem Pharmacol 43:2103-2109, 1992.
70. Dobrowsky RT, Voyksner RD, Olson NC: Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia. Am J Physiol H1455-H1463, 1991.
71. Kaminski DL, Feinstein WK, Deshpande YG: The production of experimental cholecystitis by endotoxin. Prostaglandins 47:233-245, 1994.
72. Chang TW, Wu MH, Yang YJ: Blood levels of platelet-activating factor in endotoxin-sensitive and endotoxin-resistant mice during endotoxemia. J Formos Med Assoc 91:1133-1137, 1992.
73. Autore G, Cicala C, Cirino G, Maiello FM, Mascolo N, Capasso F: Essential fatty acid-deficient diet modifies PAF levels in stomach and duodenum of endotoxin-treated rats. J Lipid Mediat Cell Signal 9:145-153, 1994.
74. Defaux JP, Thonier F, Baroggi N, Etienne A, Braquet P: Involvement of platelet-activating factor in endotoxin or ischaemia-induced intestinal hyperpermeability in the rat. J Lipid Med 7:11-21, 1993.
75. Inarrea P, Gomez-Cambronero J, Pascual J, Del Carmen Ponte M, Hernando L, Sanchez-Crespo M: Synthesis of PAF-acether and blood volume changes in Gram-negative sepsis. Immunopharmacology 9:45-52, 1985.
76. Casals-Stenzel J: Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock. Eur J Pharmacol 135:117-122, 1987.
77. Etienne A, Hecquet F, Soulard C, Spinnewyn B, Clostre F, Braquet P: In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific PAF-acether antagonist: BN 52021. Agents Actions 17:368-370, 1985.
78. Fletcher JR, Disimone AG, Earnest MA: Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia. Ann Surg 211:312-316, 1990.
79. Moore JM, Earnest MA, Disimone AG, Abumrad NN, Fletcher JR: A PAF receptor antagonistm BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia. Circ Shock 35:53-59, 1991.
80. Fletcher J, Earnest M, Moore J, Disimone A, Abumrad N: Platelet activating factor (PAF) antagonist improves survival and attenuates eicosanoid release in lethal endotoxemia. Circ Shock 27:359, 1989 (abstract).
81. Terashita ZI, Kawamura M, Takatani M, Tsushima S, Yoshimi I, Nishikawa K: Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J Pharmacol Exp Ther 260:748-55, 1992.
82. Yue TL, Farhat M, Rabinovici R, Perera PY, Vogel S, Feuerstein G: Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits. J Pharmacol Exp Ther 254:976-981, 1990.
83. Dirkes K, Harris BH, Connolly RJ, Schwaitzberg SD, Dinarello CA, Gelfand JA: Platelet activating factor-antagonist improves survival in experimental staphylococcal septicemia. J Pediatr Surg 29:1055-1058, 1994.
84. DeJoy SQ, Jeyaseelan R, Torley LW, et al: Effect of CL 184,005, a PAF-antagonist in murine model of Staphylococcus aureus-induced Gram-positive sepsis. J Infect Dis 169:150-156, 1994.
85. Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S: Biological effects of the new platelet activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4 one hydrochloride. Drug Res 44:317-322, 1994.
86. Fernandez-Gallardo S, Ortega MDP, Piergo JG, De Casanjuana MF, Sunkel C, Sanchez Crespo M: Pharmacological action of PCA 4248, a new platelet activating factor receptor antagonist: in vivo studies. J Pharmacol Exp Ther 255:34-39, 1990.
87. Ruggiero V, Chiapparino C, Manganello S, Pacello L, Foresta P, Martelli EA: Beneficial effects of a novel platelet-activating factor receptor antagonist, ST 899, on endotoxin-induced shock in mice. Shock 2:275-280, 1994.
88. Albert DH, Luo G, Magoc JT, et al: ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats. Shock 6:112-117,1996.
89. Kruse-Elliott KT, Albert DH, Summers JB, Carter GW, Zimmerman JJ, Grossman JE: Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock 5:265-273, 1996.
90. Yoshikawa D, Fumio G: Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in rats. Circ Shock 38: 29-33, 1992.
91. Herbert JM, Fraisse L, Bachy A, et al: Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist. J Lipid Med 8:31-51, 1993.
92. Herbert JM, Lespy L, Maffrand JP: Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice. Eur J Pharmacol 205:271-276, 1991.
93. Huang L, Tan X, Crawford SE, Hsueh W: platelet-activating factor and endotoxin induce tumor necrosis factor gene expression in rat intestine and liver. Immunology 83:65-69, 1994.
94. Szabo C, Chin-Chen W, Mitchell JA, Gross SS, Thiemermann C, Vane JR: Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 73:991-999, 1993.
95. Damas J: Involvement of platelet activating factor in the hypotensive response to zymosan in rats. J Lipid Med 3:333-344, 1991.
96. Qi M, Jones SB: Contribution of platelet-activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ Shock 32:153-163, 1990.
97. Ueneo A, Ishida H, Oh-ishi S: Comparative study of endotoxin-induced hypotension in kininogen-deficient rats with that in normal rats. Br J Pharmacol 114:1250-1256, 1995.
98. Yamanaka S, Iwao H, Yukimura T, Kim S, Miura K: Effect of the platelet activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the hemodynamic changes in canine experimental endotoxic shock. Br J Pharmacol 110:1501-1507, 1993.
99. Kawamura M, Kitayoshi T, Terashita Z, Fujiwara S, Takatani M, Nishikawa K: Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs. J Lipid Mediat Cell Signal 9:255-265, 1994.
100. Adnot S, Lefort J, Braquet P, Vargafting BB: Interference of the PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea-pig. Prostaglandins 32:791-802, 1986.
101. Wallace JL, Whittle BJR: Prevention of endotoxin-induced gastroinestinal damage by CV-3988, an antagonist of platelet activating factor. Eur J Pharmacol 124:209-210, 1986.
102. Handley DA, Van Valen RG, Tomesch JC, et al: Biological properties of the antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Immunopharmacology 13:125-132, 1987.
103. Wu MS, Biftu T, Doebber TW: Inhibition of the platelet activating factor induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,721), a PAF receptor antagonist. J Biol Chem 260:15639-15645, 1986.
104. Handley DA, Lee ML, Saunders RN: Evidence for a direct effect on vascular permeability of platelet activating factor induced hemoconcentration in the guinea pig. Thromb Haemost 54:756-759, 1983.
105. Sakuma Y, Shirato M, Nagaoka J, et al: Pharmacological activities of a novel thienodiazepine derivative as a platelet activating factor antagonist. Drug Res 41:1255-1259, 1991.
106. Toyufuko T, Kubo K, Kobayashi T, Kusama S: Effects of ONO-6240, a platelet activating factor antagonist, on endotoxin shock in unanesthetized sheep. Prostaglandins 31:271-281, 1986.
107. Bernat A, Herbert JM, Salel V, Lespy L, Maffrand JP: Protective effect of SR 27417, a novel antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig. J Lipid Med 51:41-48, 1992.
108. Muacevic G, Heuer HO: Platelet-activating factor antagonists in experimental shock. Arzeneimittelforschung 42:1001-1004, 1992.
109. Salari H, Demos M, Wong A: Comparative hemodynamics and cardiovascular effects of endotoxin and platelet activating factor in rats. Circ Shock 32:189-207, 1990.
110. Lagente V, Fortes ZB, Garcia-Leme J, Vargaftig BB: PAF-acether end endotoxin display similar effects on rat mesenteric microvessels: Inhibition by specific antagonists. J Pharmacol Exp Ther 247:254-261, 1988.
111. Siebeck M, Kohl J, Enders S, Spannagl M, Machleidt W: Delayed treatment with platelet activating factor receptor antagonist WEB 2086 attenuates pulmonary dysfunction in porcine endotoxin shock. J Trauma 37:745-51: 1994.
112. Siebeck M, Weipert J, Keser C, et al: A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 31:942-950, 1991.
113. Bouvier CH, Oguz Guc M, Furman BL, Parratt JR: Platelet activating factor impairs pressor responses to noradrenaline in the anaesthetized rat but does not mediate endotoxin-induced hyporeactivity. Circ Shock 42: 14-19, 1994.
114. Qi M, Jones SB: Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ Shock 32:153-163, 1990.
115. Salari H, Demos M, Wong A: Comparative hemodynamics and cardiovascular effects of endotoxin and platelet-activating factor in rat. Circ Shock 32:189-207, 1990.
116. Mulder MF, van Lambalgen AA, van Kraats AA, et al: Systemic and regional hemodynamic changes during endotoxin or platelet activating factor (PAF)-induced shock in rats. Circ Shock 41:221-229, 1993.
117. Gans ROB, DiPirro JC, Ueda Y, Niesen N, Lee KH, Brentjens JR: The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction. J Lipid Mediat 10:229-242, 1994.
118. Carrick JB, Deem Moris D, Moore JN: Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia. Equine Vet J 25:152-157, 1993.
119. Inoue Y, Kohno S, Miyazaki T, Yamaguchi K: Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. J Exp Med 163:175-185, 1991.
120. Olsen NC, Joyce PB, Fleisher LN: Role of platelet-activating factor and eicosanoids during endotoxin-induced lung injuries in pigs. J Am Physiol 258:H1674-H1686, 1990.
121. Anderson BO, Pogetti RS, Shanley PF, et al: Primed neutrophils injure rat lung through a platelet-activating factor-dependent mechanism. J Surg Res 50:510-514, 1991.
122. Ha B, Tolins JP, Vercellotti G: The role of platelet-activating factor in endotoxemic acute renal failure in the male rat. Kidney Int 33:358, 1988 (abstract).
123. Tolins JP, Vercellotti GM, Wilkowske B: Platelet-activating factor mediates endotoxin induced acute renal insufficiency in rats. J Lab Clin Med 113:316-324, 1989.
124. Wallace JL, Steel G, Whittle BJR: Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Gastroenterology 93:765-773, 1987.
125. Sorensen J, Kald B, Tagesson C, Lindahl M: Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Int Care Med 20:555-561, 1994.
126. Shinozaki K, Kawasaki T, Kambayashi J, et al: A new method of purification and sensitive bioassay of platelet-activating factor (PAF) in human whole blood. Life Sci 54:429-437, 1994.
127. Graham RM, Strahan ME, Norman KW, Watkins DN, Sturm MJ, Taylor RR: Platelet and plasma platelet activating factor in sepsis and myocardial infarction. J Lipid Mediat Cell Signal 9:167-182, 1994.
128. Ono S, Tamakuma S, Mochezuki H, et al: Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC. Surg Today 23:228-233, 1993.
129. Heuer HO, Darius H, Lohmann HF, Meyer J, Schierenberg M, Treese N: Platelet-activating factor type activity in plasma from patients with septicemia and other diseases. Lipids 26:1381-1385, 1991.
130. Diez FL, Nieto ML, Fernandez-Gallardo S, Gijion MA, Sanchez-Crespo M: Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 83:1733-1740, 1989.
131. Bussolino F, Porcellini MG, Varese L, Bosia A: Intravascular release of platelet activating factor in children with sepsis. Thromb Res 48:619-620, 1987.
132. Froon AMF, Greve JWM, Buurman WA, et al: Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock 5:313-319, 1996.
133. Dhainaut JFA, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22:1720-1728, 1994.
134. Thompson WA, Coyle S, Van Zee K, et al: The metabolic effects of platelet-activating factor in endotoxemic man. Arch Surg 129:72-79, 1994.
135. Barthelson RA, Valone FH: Platelet-activating factor stimulates expression of IL-1 beta mRNA in THP-1 cells. Lipids 26:257-261, 1991.
136. Maier RV, Hahnel GB, Fletcher JR: Platelet-activating factor augments tumor necrosis factor and procoagulant activity. J Surg Res 52:258-264, 1992.
137. Thivierge M, Rola-Plezczynski M: Up-regulation of inducible cyclooxygenase gene expression by platelet-activating factor in activated rat alveolar macrophages. J Immmunol 154:6593-6599, 1995.
138. Osterud B: Platelet-activating factor enhancement of lipopolysaccharide-induced tissue factor activity in monocytes: Requirement of platelets and granulocytes. J Leukoc Biol 51:462-465, 1992.
139. Kucey DS, Kubicki EI, Rotstein OD: Platelet-activating factor primes endotoxin-stimulated macrophage procoagulant activity. J Surg Res 50: 436-441, 1991.
140. Zhang F, Decker K: Platelet-activating factor antagonists suppress the generation of tumor necrosis factor-alpha and superoxide induced by lipopolysaccharide or phorbol ester in rat liver macrophages. Eur Cytokine Netw 5:311-317, 1994.
141. Engelberts, Von Assmuth EJU, Van der Linden CJ, Burman WA: The interrelation between TNF, IL-6, and PAF secretion induced by LPS in an in vivo and in vitro murine model. Lymphokine Cytokine Res 10:127-131, 1991.
142. Nystrom ML, Barradas A, Jeremy JY, Mikhailidis DP: Platelet shape change in whole blood: Differential effects of endotoxin. Thromb Haemost 71:646-50, 1994.
143. Brackett DJ, Lerner MR, Wilson MF: Dimethyl sulfoxide antagonizes hypotensive, metabolic and pathologic responses induced by endotoxin. Circ Shock 33:156-163, 1991.
144. Camussi G, Mariano F, Biancone L, et al: Lipopolysaccharide binding protein and CD14 modulate the synthesis of platelet-activating factor by human monocytes and mesangial cells stimulated with lipopolysaccharide. J Immunol 155:316-324, 1995.
145. Postel J, Schloerb PR, Furtado D: Pathophysiologic alterations during bacterial infusions for the study of bacteremic shock. Surgery 141:683-689, 1977.
146. Horton JW: Hemodynamic and regional blood flow responses of neonatal and adult dogs to endotoxin challenge. Circ Shock 41:26-34, 1993.
147. Parker MM, Shelhamer JH, Bachrach SL: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100: 483-490, 1987.